WO2002092078A1 - Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases - Google Patents
Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases Download PDFInfo
- Publication number
- WO2002092078A1 WO2002092078A1 PCT/IN2002/000118 IN0200118W WO02092078A1 WO 2002092078 A1 WO2002092078 A1 WO 2002092078A1 IN 0200118 W IN0200118 W IN 0200118W WO 02092078 A1 WO02092078 A1 WO 02092078A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carvedilol
- hours
- released
- pharmaceutical composition
- controlled release
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002588995A JP2004534031A (en) | 2001-05-17 | 2002-05-10 | Oral controlled release pharmaceutical composition for once daily treatment for the treatment and prevention of heart and cardiovascular diseases |
KR10-2003-7014987A KR20040037026A (en) | 2001-05-17 | 2002-05-10 | Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases |
CA002447005A CA2447005A1 (en) | 2001-05-17 | 2002-05-10 | Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases |
AU2002314515A AU2002314515B2 (en) | 2001-05-17 | 2002-05-10 | Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases |
EP02741152A EP1395258A1 (en) | 2001-05-17 | 2002-05-10 | Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases |
BR0210976-0A BR0210976A (en) | 2001-05-17 | 2002-05-10 | Oral controlled release pharmaceutical composition for once daily therapy and method for obtaining desired control over carvedilol plasma levels in humans for once daily therapy |
MXPA03010501A MXPA03010501A (en) | 2001-05-17 | 2002-05-10 | Light box and method for placing a light box in a portable position. |
HU0400607A HUP0400607A3 (en) | 2001-05-17 | 2002-05-10 | Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases |
ZA2003/09724A ZA200309724B (en) | 2001-05-17 | 2003-12-15 | Oral controlled release pharmaceutical composition for one a day therapy for the treatment and prophylaxis of cardiac and circulatory diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN464MU2001 IN191028B (en) | 2001-05-17 | 2001-05-17 | |
IN464/MUM/2001 | 2001-09-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002092078A1 true WO2002092078A1 (en) | 2002-11-21 |
Family
ID=11097247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2002/000118 WO2002092078A1 (en) | 2001-05-17 | 2002-05-10 | Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases |
Country Status (16)
Country | Link |
---|---|
US (1) | US20030035836A1 (en) |
EP (1) | EP1395258A1 (en) |
JP (1) | JP2004534031A (en) |
KR (1) | KR20040037026A (en) |
CN (1) | CN1525855A (en) |
AU (1) | AU2002314515B2 (en) |
BE (1) | BE1014328A7 (en) |
BR (1) | BR0210976A (en) |
CA (1) | CA2447005A1 (en) |
HU (1) | HUP0400607A3 (en) |
IN (1) | IN191028B (en) |
MX (1) | MXPA03010501A (en) |
PL (1) | PL370589A1 (en) |
RU (1) | RU2003133446A (en) |
WO (1) | WO2002092078A1 (en) |
ZA (1) | ZA200309724B (en) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004047837A2 (en) * | 2002-11-22 | 2004-06-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Beta-blockers having antioxidant and nitric oxide-donor activity |
WO2005079752A2 (en) * | 2004-02-11 | 2005-09-01 | Rubicon Research Private Limited | Controlled release pharmaceutical compositions with improved bioavailability |
JP2007512375A (en) * | 2003-11-25 | 2007-05-17 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | Carvedilol free base, carvedilol salt, anhydrous form or solvate thereof, corresponding pharmaceutical composition, controlled release formulation and treatment or delivery method |
US7268156B2 (en) | 2002-06-27 | 2007-09-11 | Sb Pharmco Puerto Rico Inc. | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment |
WO2008070072A2 (en) * | 2006-12-01 | 2008-06-12 | Mutual Pharmaceutical Company, Inc. | Carvedilol forms, compositions, and methods of preparation thereof |
WO2008114276A1 (en) * | 2007-03-16 | 2008-09-25 | Lupin Limited | Novel oral controlled release composition of carvedilol |
EP1929998A3 (en) * | 2001-09-21 | 2008-11-26 | Egalet A/S | Controlled release solid dispersions of carvedilol |
US7649010B2 (en) | 2002-06-27 | 2010-01-19 | SmithKline Beechman Cork Limited | Carvedilol hydrobromide |
EP2155171A1 (en) * | 2007-04-27 | 2010-02-24 | Libbs Farmacêutica Ltda | Osmotic form for controlled release of active principles |
US7750036B2 (en) | 2003-11-25 | 2010-07-06 | Sb Pharmco Puerto Rico Inc. | Carvedilol salts, corresponding compositions, methods of delivery and/or treatment |
US7883722B2 (en) | 1998-04-03 | 2011-02-08 | Egalet Ltd. | Controlled release composition |
US8298581B2 (en) | 2003-03-26 | 2012-10-30 | Egalet A/S | Matrix compositions for controlled delivery of drug substances |
US8449914B2 (en) | 2002-11-08 | 2013-05-28 | Egalet Ltd. | Controlled release carvedilol compositions |
US8609143B2 (en) | 2001-09-21 | 2013-12-17 | Egalet Ltd. | Morphine polymer release system |
US8617605B2 (en) | 2001-09-21 | 2013-12-31 | Egalet Ltd. | Polymer release system |
KR20140104341A (en) | 2013-02-20 | 2014-08-28 | 주식회사 종근당 | Pharmaceutical composition consisting of sustained-release pellets |
US8877241B2 (en) | 2003-03-26 | 2014-11-04 | Egalet Ltd. | Morphine controlled release system |
US9005660B2 (en) | 2009-02-06 | 2015-04-14 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
US9023394B2 (en) | 2009-06-24 | 2015-05-05 | Egalet Ltd. | Formulations and methods for the controlled release of active drug substances |
US9044402B2 (en) | 2012-07-06 | 2015-06-02 | Egalet Ltd. | Abuse-deterrent pharmaceutical compositions for controlled release |
US9642809B2 (en) | 2007-06-04 | 2017-05-09 | Egalet Ltd. | Controlled release pharmaceutical compositions for prolonged effect |
KR20170093589A (en) | 2016-02-05 | 2017-08-16 | 삼진제약주식회사 | Carvedilol immediate release formulation having improved madescent |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8101209B2 (en) * | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
EP1499310A4 (en) * | 2002-04-30 | 2005-12-07 | Sb Pharmco Inc | Carvedilol monocitrate monohydrate |
ES2335008T3 (en) * | 2003-04-24 | 2010-03-18 | Jagotec Ag | COMPRESSED WITH COLORED NUCLEUS. |
JP5026077B2 (en) * | 2003-09-12 | 2012-09-12 | アムジエン・インコーポレーテツド | Calcium receptor-active compound rapid dissolution formulation |
US7120743B2 (en) | 2003-10-20 | 2006-10-10 | Micron Technology, Inc. | Arbitration system and method for memory responses in a hub-based memory system |
EP1686967A4 (en) * | 2003-11-25 | 2012-08-08 | Smithkline Beecham Cork Ltd | Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods |
EP1895989A2 (en) * | 2005-06-03 | 2008-03-12 | Egalet A/S | A solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids |
US8367112B2 (en) * | 2006-02-28 | 2013-02-05 | Alkermes Pharma Ireland Limited | Nanoparticulate carverdilol formulations |
WO2007144785A2 (en) * | 2006-03-26 | 2007-12-21 | Uti Limited Partnership | Ryanodine receptor inhibitors and methods relating thereto |
SG174026A1 (en) | 2006-08-03 | 2011-09-29 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of rheumatoid disease |
US20090028935A1 (en) * | 2006-12-01 | 2009-01-29 | Kristin Arnold | Carvedilol forms, compositions, and methods of preparation thereof |
WO2008086804A2 (en) * | 2007-01-16 | 2008-07-24 | Egalet A/S | Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse |
CA2749646A1 (en) * | 2009-01-26 | 2010-07-29 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of asthma |
TWI415604B (en) * | 2009-09-29 | 2013-11-21 | Tsh Biopharm Corp Ltd | Controlled release carvediolol formulation |
WO2011102506A1 (en) * | 2010-02-22 | 2011-08-25 | 第一三共株式会社 | Sustained-release solid preparation for oral use |
WO2011102504A1 (en) | 2010-02-22 | 2011-08-25 | 第一三共株式会社 | Sustained-release solid preparation for oral use |
BR112015004190A2 (en) | 2012-09-03 | 2017-07-04 | Daiichi Sankyo Co Ltd | sustained release pharmaceutical composition, and method for producing a sustained release pharmaceutical composition |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998040053A1 (en) * | 1997-03-11 | 1998-09-17 | Darwin Discovery Limited | Dosage forms comprising separate portions of r- and s-enantiomers |
WO2001051036A1 (en) * | 2000-01-14 | 2001-07-19 | Osmotica Corp. | Osmotic device within an osmotic device |
WO2001051035A1 (en) * | 2000-01-14 | 2001-07-19 | Osmotica Corp. | Combined diffusion/osmotic pumping drug delivery system |
WO2001074356A1 (en) * | 2000-04-03 | 2001-10-11 | F. Hoffmann-La Roche Ag | Concentrated solutions of carvedilol |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2815926A1 (en) * | 1978-04-13 | 1979-10-18 | Boehringer Mannheim Gmbh | NEW CARBAZOLYL- (4) -OXY-PROPANOLAMINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US5972389A (en) * | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
IE970588A1 (en) * | 1997-08-01 | 2000-08-23 | Elan Corp Plc | Controlled release pharmaceutical compositions containing tiagabine |
US20020054911A1 (en) * | 2000-05-11 | 2002-05-09 | Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi | Novel oral dosage form for carvedilol |
PE20001302A1 (en) * | 1998-11-27 | 2000-11-30 | Hoffmann La Roche | PREPARATIONS OF A PHARMACEUTICAL COMBINATION CONTAINING CARVEDILOL AND HYDROCHLOROTHIAZIDE |
JP2003514019A (en) * | 1999-11-15 | 2003-04-15 | スミスクライン・ビーチャム・コーポレイション | Carvedilol methanesulfonate |
JP2004518734A (en) * | 2000-10-24 | 2004-06-24 | スミスクライン・ビーチャム・コーポレイション | A new formulation of carvedilol |
-
2001
- 2001-05-17 IN IN464MU2001 patent/IN191028B/en unknown
-
2002
- 2002-05-10 MX MXPA03010501A patent/MXPA03010501A/en unknown
- 2002-05-10 BR BR0210976-0A patent/BR0210976A/en not_active IP Right Cessation
- 2002-05-10 CA CA002447005A patent/CA2447005A1/en not_active Abandoned
- 2002-05-10 JP JP2002588995A patent/JP2004534031A/en active Pending
- 2002-05-10 HU HU0400607A patent/HUP0400607A3/en unknown
- 2002-05-10 PL PL02370589A patent/PL370589A1/en not_active Application Discontinuation
- 2002-05-10 WO PCT/IN2002/000118 patent/WO2002092078A1/en active Application Filing
- 2002-05-10 KR KR10-2003-7014987A patent/KR20040037026A/en not_active Application Discontinuation
- 2002-05-10 CN CNA028101294A patent/CN1525855A/en active Pending
- 2002-05-10 EP EP02741152A patent/EP1395258A1/en active Pending
- 2002-05-10 RU RU2003133446/15A patent/RU2003133446A/en unknown
- 2002-05-10 AU AU2002314515A patent/AU2002314515B2/en not_active Ceased
- 2002-05-16 BE BE2002/0322A patent/BE1014328A7/en not_active IP Right Cessation
- 2002-08-19 US US10/146,670 patent/US20030035836A1/en not_active Abandoned
-
2003
- 2003-12-15 ZA ZA2003/09724A patent/ZA200309724B/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998040053A1 (en) * | 1997-03-11 | 1998-09-17 | Darwin Discovery Limited | Dosage forms comprising separate portions of r- and s-enantiomers |
WO2001051036A1 (en) * | 2000-01-14 | 2001-07-19 | Osmotica Corp. | Osmotic device within an osmotic device |
WO2001051035A1 (en) * | 2000-01-14 | 2001-07-19 | Osmotica Corp. | Combined diffusion/osmotic pumping drug delivery system |
WO2001074356A1 (en) * | 2000-04-03 | 2001-10-11 | F. Hoffmann-La Roche Ag | Concentrated solutions of carvedilol |
Cited By (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7883722B2 (en) | 1998-04-03 | 2011-02-08 | Egalet Ltd. | Controlled release composition |
US9694080B2 (en) | 2001-09-21 | 2017-07-04 | Egalet Ltd. | Polymer release system |
US9707179B2 (en) | 2001-09-21 | 2017-07-18 | Egalet Ltd. | Opioid polymer release system |
US8617605B2 (en) | 2001-09-21 | 2013-12-31 | Egalet Ltd. | Polymer release system |
US8609143B2 (en) | 2001-09-21 | 2013-12-17 | Egalet Ltd. | Morphine polymer release system |
EP1929998A3 (en) * | 2001-09-21 | 2008-11-26 | Egalet A/S | Controlled release solid dispersions of carvedilol |
US7759384B2 (en) | 2002-06-27 | 2010-07-20 | Smithkline Beecham (Cork) Limited | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment |
US7268156B2 (en) | 2002-06-27 | 2007-09-11 | Sb Pharmco Puerto Rico Inc. | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment |
US7902378B2 (en) | 2002-06-27 | 2011-03-08 | Smithkline Beecham (Cork) Limited | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment |
US7893100B2 (en) | 2002-06-27 | 2011-02-22 | Sb Pharmco Puerto Rico Inc. | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment |
US7626041B2 (en) | 2002-06-27 | 2009-12-01 | Smithkline Beecham (Cork) Ltd | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment |
US7649010B2 (en) | 2002-06-27 | 2010-01-19 | SmithKline Beechman Cork Limited | Carvedilol hydrobromide |
US8449914B2 (en) | 2002-11-08 | 2013-05-28 | Egalet Ltd. | Controlled release carvedilol compositions |
WO2004047837A3 (en) * | 2002-11-22 | 2004-09-16 | Yissum Res Dev Co | Beta-blockers having antioxidant and nitric oxide-donor activity |
WO2004047837A2 (en) * | 2002-11-22 | 2004-06-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Beta-blockers having antioxidant and nitric oxide-donor activity |
US8298581B2 (en) | 2003-03-26 | 2012-10-30 | Egalet A/S | Matrix compositions for controlled delivery of drug substances |
US8877241B2 (en) | 2003-03-26 | 2014-11-04 | Egalet Ltd. | Morphine controlled release system |
US9884029B2 (en) | 2003-03-26 | 2018-02-06 | Egalet Ltd. | Morphine controlled release system |
US9375428B2 (en) | 2003-03-26 | 2016-06-28 | Egalet Ltd. | Morphine controlled release system |
JP2007512375A (en) * | 2003-11-25 | 2007-05-17 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | Carvedilol free base, carvedilol salt, anhydrous form or solvate thereof, corresponding pharmaceutical composition, controlled release formulation and treatment or delivery method |
JP2012140440A (en) * | 2003-11-25 | 2012-07-26 | Smithkline Beecham (Cork) Ltd | Carvedilol free base, carvedilol salt, anhydrous form or solvate thereof, corresponding pharmaceutical composition, controlled release formulation, and treatment or delivery method |
US7750036B2 (en) | 2003-11-25 | 2010-07-06 | Sb Pharmco Puerto Rico Inc. | Carvedilol salts, corresponding compositions, methods of delivery and/or treatment |
USRE47084E1 (en) | 2003-11-25 | 2018-10-16 | Flamel Ireland Limited | Oral medicinal product with modified release of at least one active principle in multimicrocapsular form |
WO2005079752A3 (en) * | 2004-02-11 | 2006-12-14 | Rubicon Res Private Ltd | Controlled release pharmaceutical compositions with improved bioavailability |
WO2005079752A2 (en) * | 2004-02-11 | 2005-09-01 | Rubicon Research Private Limited | Controlled release pharmaceutical compositions with improved bioavailability |
WO2008070072A2 (en) * | 2006-12-01 | 2008-06-12 | Mutual Pharmaceutical Company, Inc. | Carvedilol forms, compositions, and methods of preparation thereof |
WO2008070072A3 (en) * | 2006-12-01 | 2009-04-16 | Mutual Pharmaceutical Co | Carvedilol forms, compositions, and methods of preparation thereof |
WO2008114276A1 (en) * | 2007-03-16 | 2008-09-25 | Lupin Limited | Novel oral controlled release composition of carvedilol |
EP2155171A4 (en) * | 2007-04-27 | 2011-08-10 | Libbs Farmaceutica Ltda | Osmotic form for controlled release of active principles |
EP2155171A1 (en) * | 2007-04-27 | 2010-02-24 | Libbs Farmacêutica Ltda | Osmotic form for controlled release of active principles |
US9642809B2 (en) | 2007-06-04 | 2017-05-09 | Egalet Ltd. | Controlled release pharmaceutical compositions for prolonged effect |
US9358295B2 (en) | 2009-02-06 | 2016-06-07 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
US9005660B2 (en) | 2009-02-06 | 2015-04-14 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
US9023394B2 (en) | 2009-06-24 | 2015-05-05 | Egalet Ltd. | Formulations and methods for the controlled release of active drug substances |
US9044402B2 (en) | 2012-07-06 | 2015-06-02 | Egalet Ltd. | Abuse-deterrent pharmaceutical compositions for controlled release |
US9549899B2 (en) | 2012-07-06 | 2017-01-24 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
KR20140104341A (en) | 2013-02-20 | 2014-08-28 | 주식회사 종근당 | Pharmaceutical composition consisting of sustained-release pellets |
KR20170093589A (en) | 2016-02-05 | 2017-08-16 | 삼진제약주식회사 | Carvedilol immediate release formulation having improved madescent |
Also Published As
Publication number | Publication date |
---|---|
BR0210976A (en) | 2004-10-05 |
JP2004534031A (en) | 2004-11-11 |
IN191028B (en) | 2003-09-13 |
CN1525855A (en) | 2004-09-01 |
ZA200309724B (en) | 2005-05-25 |
HUP0400607A3 (en) | 2005-07-28 |
RU2003133446A (en) | 2005-03-10 |
US20030035836A1 (en) | 2003-02-20 |
PL370589A1 (en) | 2005-05-30 |
CA2447005A1 (en) | 2002-11-21 |
MXPA03010501A (en) | 2004-03-02 |
BE1014328A7 (en) | 2003-08-05 |
KR20040037026A (en) | 2004-05-04 |
HUP0400607A2 (en) | 2004-07-28 |
AU2002314515B2 (en) | 2007-08-16 |
EP1395258A1 (en) | 2004-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002314515B2 (en) | Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases | |
AU2002314515A1 (en) | Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases | |
KR101774676B1 (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
JP5420590B2 (en) | pH independent extended release pharmaceutical composition | |
JPH061716A (en) | Medical prescription having long-term releasability of active ingredient | |
ZA200402369B (en) | Dosage form for treatment of diabetes mellitus | |
NO175405B (en) | Process for the preparation of a slow release pharmaceutical composition which is not an injection fluid | |
KR20080059212A (en) | 3-(2-dimethylaminomethyl cyclohexyl) phenol retard formulation | |
WO2003075830A2 (en) | Oral controlled drug delivery system containing carbamazepine | |
US20100055177A1 (en) | Modified release composition of levetiracetam and process for the preparation thereof | |
EP1556014A1 (en) | Sustained release compositions containing alfuzosin | |
WO2003011256A1 (en) | Oral controlled release pharmaceutical composition of a prokinetic agent | |
EP2010158B1 (en) | Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix | |
WO2003030920A1 (en) | An antispasmodic agent spaced drug delivery system | |
CN114588124B (en) | Delayed release pharmaceutical composition | |
US20080063707A1 (en) | Controlled release tablet formulations for the prevention of arrhythmias | |
US20150209292A1 (en) | Controlled release formulations and preparation method thereof | |
EP3941443B1 (en) | Sustained release composition comprising tapentadol oxalate and method of preparation thereof | |
JP4696210B2 (en) | Sustained-release tablets containing isosorbide-5-mononitrate as an active ingredient and method for producing the same | |
US20040228918A1 (en) | Granule modulating hydrogel system | |
US20040265381A1 (en) | Anti-asthmatic drug (asmakure) from indigenous herbs to cure the disease asthma | |
MXPA01007814A (en) | Ph independent extended release pharmaceutical formulation | |
WO2013007360A1 (en) | Controlled release pharmaceutical composition of non-ergoline dopamine agonist | |
CZ335996A3 (en) | Pharmaceutical composition with prolonged release containing nifedipin and process of its preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002314515 Country of ref document: AU Ref document number: 2447005 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002588995 Country of ref document: JP Ref document number: 028101294 Country of ref document: CN Ref document number: PA/A/2003/010501 Country of ref document: MX Ref document number: 1020037014987 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200309724 Country of ref document: ZA Ref document number: 2002741152 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002741152 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |